Page last updated: 2024-12-11

lactacystin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID6610292
CHEMBL ID374308
CHEBI ID52722
SCHEMBL ID18254
MeSH IDM0185517

Synonyms (36)

Synonym
BCBCMAP01_000029
BIO1_000949 ,
BIO1_001438
BIO1_000460
SMP1_000173
lactacystin ,
133343-34-7
lactacystin, >=90% (hplc)
NCGC00162444-01
lactacystin, synthetic
l-cysteine, n-acetyl-, 3-hydroxy-2-(1-hydroxy-2-methylpropyl)-4-methyl-5-oxo-2-pyrrolidinecarboxylate (ester), (2r-(2alpha,2(s*),3alpha,4alpha))-
c15h24n2o7s
CHEMBL374308
n-acetyl-s-({(2r,3s,4r)-3-hydroxy-2-[(1s)-1-hydroxy-2-methylpropyl]-4-methyl-5-oxopyrrolidin-2-yl}carbonyl)-l-cysteine
CHEBI:52722 ,
(+)-lactacystin
NCGC00162444-02
(2r)-2-acetamido-3-[(2r,3s,4r)-3-hydroxy-2-[(1s)-1-hydroxy-2-methylpropyl]-4-methyl-5-oxopyrrolidine-2-carbonyl]sulfanylpropanoic acid
bdbm50432548
AKOS025294316
SCHEMBL18254
(2r,3s,4r)-3-hydroxy-2-[(1s)-1-hydroxy-2-methylpropyl]-4-methyl-5-oxo-2-pyrrolidinecarboxy-n-acetyl-l-cysteine thioester
3s-hydroxy-2r-(1-hydroxy-2-methylpropyl)-4r-methyl-5-oxo-2-pyrrolidinecarboxylate-n-acetyl-l-cysteine
HB3953
J-006356
(r)-2-acetamido-3-((2r,3s,4r)-3-hydroxy-2-((s)-1-hydroxy-2-methylpropyl)-4-methyl-5-oxopyrrolidine-2-carbonylthio)propanoic acid
DTXSID50897422
(2r)-2-acetamido-3-({(2r,3s,4r)-3-hydroxy-2-[(1s)-1-hydroxy-2-methylpropyl]-4-methyl-5-oxopyrrolidine-2-carbonyl}sulfanyl)propanoic acidlactacystin
SR-01000946977-1
sr-01000946977
l-cysteine, n-acetyl-s-[(3s,4r)-3-hydroxy-2-[(1s)-1-hydroxy-2-methylpropyl]-4-methyl-5-oxo-d-prolyl]-
HY-16594
CS-0007504
n-acetyl-s-{[(2r,3s,4r)-3-hydroxy-2-(1-hydroxy-2-methylpropyl)-4-methyl-5-oxo-2-pyrrolidinyl]carbonyl}-l-cysteine
n-acetyl-s-((2r,3s,4r)-3-hydroxy-2-((s)-1-hydroxy-2-methylpropyl)-4-methyl-5-oxopyrrolidine-2-carbonyl)-l-cysteine
FS-6660

Research Excerpts

Overview

Lactacystin is a Streptomyces metabolite that inhibits cell cycle progression and induces neurite outgrowth in a murine neuroblastoma cell line. It has been used to destroy dopamine (DA) neurons in animal models of Parkinson's disease (PD)

ExcerptReferenceRelevance
"Lactacystin is a selective UPS inhibitor recently used to destroy dopamine (DA) neurons in animal models of Parkinson's disease (PD). "( Decreased behavioral response to intranigrally administered GABAA agonist muscimol in the lactacystin model of Parkinson's disease may result from partial lesion of nigral non-dopamine neurons: comparison to the classical neurotoxin 6-OHDA.
Czarnecka, A; Kamińska, K; Konieczny, J; Lenda, T; Nowak, P, 2015
)
2.08
"Lactacystin is a specific inhibitor of the proteasome and is a potent apoptosis inductor in resting peripheral B-CLL cells."( Cycling B-CLL cells are highly susceptible to inhibition of the proteasome: involvement of p27, early D-type cyclins, Bax, and caspase-dependent and -independent pathways.
Bogner, C; Decker, T; Hipp, S; Peschel, C; Ringshausen, I; Schneller, F, 2003
)
1.04
"Lactacystin is a Streptomyces metabolite that inhibits cell cycle progression and induces neurite outgrowth in a murine neuroblastoma cell line. "( Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin.
Choi, S; Corey, EJ; Fenteany, G; Lane, WS; Schreiber, SL; Standaert, RF, 1995
)
1.95
"Lactacystin is a Streptomyces metabolite that inhibits cell cycle progression and induces differentiation in a murine neuroblastoma cell line. "( Mechanistic studies on the inactivation of the proteasome by lactacystin: a central role for clasto-lactacystin beta-lactone.
Cruikshank, AA; Dick, LR; Grenier, L; Melandri, FD; Nunes, SL; Stein, RL, 1996
)
1.98
"Lactacystin is a microbial metabolite known to inhibit only the protease activity of the proteasome, which is required for NF-kappa B translocation."( Proteasome regulation of Fas ligand cytotoxicity.
Cui, H; Ju, ST; Matsui, K; Omura, S; Schauer, SL; Sonenshein, GE, 1997
)
1.02
"Lactacystin is a very specific 26S proteasome inhibitor and represents an excellent tool for demonstrating that a pathway exhibits proteasome-dependent biochemical regulation."( Inhibition of the 26S proteasome induces expression of GLCLC, the catalytic subunit for gamma-glutamylcysteine synthetase.
Borrelli, MJ; Domann, FE; Freeman, ML; Meredith, MJ; Sekhar, KR; Soltaninassab, SR; Xu, ZQ, 2000
)
1.03
"Lactacystin (LC) is a specific inhibitor of the proteasome, and has recently been shown to induce apoptosis in certain cell lines. "( Lactacystin activates FLICE (caspase 8) protease and induces apoptosis in Fas-resistant adult T-cell leukemia cell lines.
Hata, T; Hayashibara, T; Honda, M; Joh, T; Kamihira, S; Maeda, T; Miyazaki, Y; Mori, N; Nohda, K; Sugahara, K; Tawara, M; Tomonaga, M; Tsuruda, K; Yamada, Y, 2000
)
3.19
"Lactacystin is a selective inhibitor of the proteasome that can inhibit the ubiquitin pathway."( Lactacystin enhances cisplatin sensitivity in resistant human ovarian cancer cell lines via inhibition of DNA repair and ERCC-1 expression.
Li, QQ; Mimnaugh, EG; Neckers, L; Reed, E; Yu, JJ; Yunmbam, MK; Zhong, X, 2001
)
2.47

Effects

Lactacystin has a novel gamma-lactam thioester structure and is also a selective and strong proteasome inhibitor. LactacyStin has been used to establish rodent models of Parkinson disease.

ExcerptReferenceRelevance
"Lactacystin has a novel gamma-lactam thioester structure and is also a selective and strong proteasome inhibitor."( Efficient total synthesis of novel bioactive microbial metabolites.
Hirose, T; Omura, S; Sunazuka, T, 2008
)
1.07
"Lactacystin has been used to establish rodent models of Parkinson disease (PD), with cerebral α-synuclein inclusions. "( [
Chen, ZA; Hsiao, IT; Hsu, CH; Huang, SL; Kung, MP; Lin, KJ; Weng, CC; Wey, SP; Yen, TC, 2017
)
1.9
"lactacystin) in animals has consistently produced important features of the disease."( Direct intranigral administration of an ubiquitin proteasome system inhibitor in rat: behavior, positron emission tomography, immunohistochemistry.
Dinelle, K; Doudet, DJ; Flores, J; Jing, Y; Mackey, S, 2013
)
1.11
"Lactacystin has a novel gamma-lactam thioester structure and is also a selective and strong proteasome inhibitor."( Efficient total synthesis of novel bioactive microbial metabolites.
Hirose, T; Omura, S; Sunazuka, T, 2008
)
1.07

Actions

Lactacystin was found to inhibit the beta-cleavage of APP, leading to a proportional decrease in Abeta production. It did not inhibit the expression of nuclear transcription factor Oct-1.

ExcerptReferenceRelevance
"Lactacystin did not inhibit gamma-secretase activity but was found to inhibit the beta-cleavage of APP, leading to a proportional decrease in Abeta production."( Lactacystin decreases amyloid-beta peptide production by inhibiting beta-secretase activity.
Courtoy, PJ; de Diesbach, P; Feyt, C; Huysseune, S; Kienlen-Campard, P; N'Kuli, F; Octave, JN, 2006
)
2.5
"Lactacystin did not inhibit the expression of nuclear transcription factor Oct-1."( Proteasome regulation of activation-induced T cell death.
Cui, H; Ju, ST; Matsui, K; Matulka, RA; Omura, S; Schauer, SL; Sonenshein, GE, 1997
)
1.02

Treatment

Lactacystin treatment increased the amount of nitric oxide and tumor necrosis factor alpha (TNF-alpha) in culture media containing murine microglia (BV-2) The treatment resulted in almost complete prevention of in vivo neovascularization in the developing chick embryo chorioallantoic membrane.

ExcerptReferenceRelevance
"Lactacystin treatment also resulted in an accumulation of ubiquitinated proteins and caused increase in the amount of endoplasmic reticulum membranes in the parasite."( Characterisation of 20S Proteasome in Tritrichomonas foetus and Its Role during the Cell Cycle and Transformation into Endoflagellar Form.
Benchimol, M; Gonzaga, L; Menna-Barreto, RF; Pereira-Neves, A, 2015
)
1.14
"Lactacystin treatment also augmented protein levels of GCLC, xCT, and GGT, but significant levels were not detected until 48 h after initiation of lactacystin treatment."( The proteasome inhibitor lactacystin enhances GSH synthesis capacity by increased expression of antioxidant components in an Nrf2-independent, but p38 MAPK-dependent manner in rat colorectal carcinoma cells.
Huseby, NE; Moens, U; Ravuri, C, 2016
)
1.46
"Lactacystin treatment suppressed interleukin (IL)-2, interferon (IFN)gamma, and IL-13 production similarly in both activated Jurkat cells and primary splenocytes."( Differential effects of lactacystin on cytokine production in activated Jurkat cells and murine splenocytes.
Qureshi, N; Rockwell, CE, 2010
)
1.39
"Lactacystin treatment significantly induced apoptosis in RPE-J cells."( Early mitochondrial hyperpolarization and intracellular alkalinization in lactacystin-induced apoptosis of retinal pigment epithelial cells.
Ahn, HB; Bae, HR; Kim, JM; Lee, JM; Park, BS; Park, WC; Rho, JH; Rho, SH; Yoo, KW; Yoo, YH; Yoon, HS, 2003
)
1.27
"In lactacystin-treated cells, we observe a failure of Met dephosphorylation as well as Met degradation."( Endosomal dynamics of Met determine signaling output.
Carter, S; Clague, MJ; Hammond, DE; McCullough, J; Urbé, S; Vande Woude, G, 2003
)
0.83
"Lactacystin pretreatment failed to prevent TRG-induced decrease in Hsp 70 protein."( Troglitazone reduces heat shock protein 70 content in primary rat hepatocytes by a ubiquitin proteasome independent mechanism.
Bharadwaj, LA; Davies, GF; Ovsenek, N; Roesler, WJ, 2003
)
1.04
"Lactacystin treatment decreased the p32 zymogen and evoked the accumulation of the p17 and p12 subunits."( Preservation of caspase-3 subunits from degradation contributes to apoptosis evoked by lactacystin: any single lysine or lysine pair of the small subunit is sufficient for ubiquitination.
Chen, L; Smith, JB; Smith, L; Wang, Z, 2003
)
1.26
"Lactacystin pretreatment had minor effects on postischemic recovery of isolated hearts exposed to 30 min global ischemia and 60 min reperfusion."( Proteasome mediates removal of proteins oxidized during myocardial ischemia.
Divald, A; Powell, SR, 2006
)
1.06
"Lactacystin treatment increased the amount of nitric oxide and tumor necrosis factor alpha (TNF-alpha) in culture media containing murine microglia (BV-2)."( BV-2 stimulation by lactacystin results in a strong inflammatory reaction and apoptotic neuronal death in SH-SY5Y cells.
Ahn, TB; Jeon, BS; Kwon, SJ; Yoon, MY, 2008
)
1.39
"Lactacystin treatment resulted in almost complete prevention of in vivo neovascularization in the developing chick embryo chorioallantoic membrane."( The proteasome is involved in angiogenesis.
Nakamura, M; Oikawa, T; Omura, S; Sasaki, T; Shimamura, M; Tanahashi, N; Tanaka, K, 1998
)
1.02
"Lactacystin treatment disrupted the HLA-A2 clusters, but had no effect on the A2-T134K clusters."( Clustering of peptide-loaded MHC class I molecules for endoplasmic reticulum export imaged by fluorescence resonance energy transfer.
Edidin, M; Pentcheva, T, 2001
)
1.03
"The treatment with lactacystin induced the nuclear translocation of NF-E2-related factor 2 (Nrf2) and increased the level of mRNA for gamma-glutamylcysteine synthetase, a rate-limiting enzyme in glutathione synthesis."( Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease.
Akaike, A; Izumi, Y; Katsuki, H; Kume, T; Sawada, H; Shimohama, S; Yamamoto, N, 2007
)
0.66
"Treatment with lactacystin, a proteasome inhibitor, significantly suppressed 6-hydroxydopamine (6-OHDA)-induced toxicity and oxidative stress in PC12 cells."( [Dopaminergic neuroprotection via Nrf2-ARE pathway activation: identification of an activator from green perilla leaves].
Izumi, Y, 2013
)
0.73
"Pretreatment with lactacystin enhanced the alkaline phosphatase (ALP) activity induced by BMP2, BMP4 or BMP7, but lactacystin did not induce ALP in the absence of BMPs."( Lactacystin, a proteasome inhibitor, enhances BMP-induced osteoblastic differentiation by increasing active Smads.
Fukushima, H; Hirata, S; Hosokawa, R; Ito, Y; Jimi, E; Katagiri, T; Seo, Y; Zhang, M, 2011
)
2.14
"Treatment with lactacystin (1 micro m) caused only limited cell viability loss, even though it induced a marked inhibition of proteasomal activities."( Proteasomal inhibition causes the formation of protein aggregates containing a wide range of proteins, including nitrated proteins.
Halliwell, B; Hyun, DH; Jenner, P; Lee, M, 2003
)
0.66
"Treatment with lactacystin, a potent inhibitor of proteasome, restored alpha5 integrin levels in FGFR2 mutant osteoblasts."( Cbl-mediated ubiquitination of alpha5 integrin subunit mediates fibronectin-dependent osteoblast detachment and apoptosis induced by FGFR2 activation.
Bouvard, D; Didelot, N; Guenou, H; Kaabeche, K; Listrat, A; Marie, PJ, 2005
)
0.67
"Treatment with lactacystin/pCPP : SA polymers with loading concentrations of 1.0, 1.3, and 1.5% prolonged survival of animals intracranially challenged with 9L when polymers where inserted in the day of tumor implantation."( Lactacystin exhibits potent anti-tumor activity in an animal model of malignant glioma when administered via controlled-release polymers.
Brem, H; DiMeco, F; Fiorindi, A; Gaini, SM; Legnani, FG; Olivi, A; Pradilla, G; Recinos, PF; Thai, QA; Tyler, BM, 2006
)
2.12
"Treatment with lactacystin (an inhibitor of the proteasome) or heat shock leads to similar levels of p53 accumulation in normal and AT fibroblasts, but the p53 protein lacks a phosphorylated serine 15."( Requirement of ATM in phosphorylation of the human p53 protein at serine 15 following DNA double-strand breaks.
Nakagawa, K; Tamai, K; Taya, Y; Yamaizumi, M, 1999
)
0.64
"Treatment with lactacystin (26S proteosome inhibitor), which arrest cell cycle at M phase, redistributed PSs into centrosome-kinetochore microtubule."( Subcellular localization of presenilins during mouse preimplantation development.
Chang, KA; Choi, SH; Geum, DH; Jeong, SJ; Kim, HS; Kim, K; Lee, JH; Lee, SG; Park, CH; Rah, JC; Seo, JH; Suh, YH, 2000
)
0.65

Toxicity

ExcerptReferenceRelevance
" These results suggest that ER stress mediates polyglutamine toxicity prior to UPS impairment during the initial stages of these toxic effects."( ER stress is the initial response to polyglutamine toxicity in PC12 cells.
Fujikake, N; Hamada, M; Hatano, O; Ikeuchi, T; Isosaki, M; Nagai, Y; Nakayama, H; Shimoke, K; Yoshizumi, M; Zhao, J, 2008
)
0.35
"Cisplatin is commonly used as a therapeutic agent, despite its known adverse side effects and the occurrence of drug resistance."( Proteasome inhibitor lactacystin enhances cisplatin cytotoxicity by increasing endoplasmic reticulum stress-associated apoptosis in HeLa cells.
Li, D; Li, Z; Liu, S; Wang, C; Wang, Y; Xu, Y; Yu, Y; Zeng, L; Zhang, L, 2015
)
0.74

Compound-Compound Interactions

ExcerptReferenceRelevance
"The present study investigated the mechanism underlying the antitumor activity of the histone deacetylases inhibitor valproic acid (VPA), alone and in combination with doxorubicin, a synthetic chenodeoxycholic acid derivative (HS-1200), or the proteasome inhibitor lactacystin on cultured anaplastic thyroid carcinoma KAT-18 cells."( Efficacy on anaplastic thyroid carcinoma of valproic acid alone or in combination with doxorubicin, a synthetic chenodeoxycholic acid derivative, or lactacystin.
Kang, DY; Kim, SH; Kim, TH; Park, KJ; Park, MK; Suh, H; Yoo, YH, 2009
)
0.73

Bioavailability

ExcerptReferenceRelevance
" Although many studies described the use of OPG during the treatment of bone diseases, its bioavailability and the mechanism by which the cells control the extracellular OPG remains blurred."( OPG/membranous--RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation.
Couillaud-Battaglia, S; Fortun, Y; Heymann, D; Padrines, M; Redini, F; Tat, SK; Theoleyre, S, 2006
)
0.33

Dosage Studied

ExcerptRelevanceReference
" However, a higher gene dosage of the transgenic Bcl-2 was required for protection against Dex, compared to the PMA and/or ionomycin-induced apoptosis."( Biochemical and kinetic characterization of the glucocorticoid-induced apoptosis of immature CD4+CD8+ thymocytes.
Ivanov, VN; Nikolić-Zugić, J, 1998
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
lactamCyclic amides of amino carboxylic acids, having a 1-azacycloalkan-2-one structure, or analogues having unsaturation or heteroatoms replacing one or more carbon atoms of the ring.
S-substituted L-cysteine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
COVID-19, thrombosis and anticoagulation75

Protein Targets (21)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency0.28180.00798.23321,122.0200AID2551
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Proteasome subunit beta type-11Homo sapiens (human)IC50 (µMol)0.25900.00130.70995.0000AID277357
Proteasome subunit alpha type-7Homo sapiens (human)IC50 (µMol)0.25900.00130.70995.0000AID277357
Proteasome subunit beta type-1Homo sapiens (human)IC50 (µMol)16.08630.00060.73766.3700AID1382145; AID1382148; AID277357
Proteasome subunit alpha type-1Homo sapiens (human)IC50 (µMol)0.25900.00130.70995.0000AID277357
Proteasome subunit alpha type-2Homo sapiens (human)IC50 (µMol)0.25900.00130.70995.0000AID277357
Proteasome subunit alpha type-3Homo sapiens (human)IC50 (µMol)0.25900.00130.70995.0000AID277357
Proteasome subunit alpha type-4Homo sapiens (human)IC50 (µMol)0.25900.00130.70995.0000AID277357
Proteasome subunit beta type-8Homo sapiens (human)IC50 (µMol)1.62950.00130.36985.0000AID1128235; AID277357
Proteasome subunit beta type-9Homo sapiens (human)IC50 (µMol)0.25900.00100.76115.0000AID277357
Proteasome subunit alpha type-5Homo sapiens (human)IC50 (µMol)0.25900.00130.70995.0000AID277357
Proteasome subunit beta type-4Homo sapiens (human)IC50 (µMol)0.25900.00130.70995.0000AID277357
Proteasome subunit beta type-6Homo sapiens (human)IC50 (µMol)0.25900.00130.69125.0000AID277357
Proteasome subunit beta type-5Homo sapiens (human)IC50 (µMol)2.72320.00050.939410.0000AID1128234; AID1204607; AID1382147; AID1382150; AID277357; AID737372
Proteasome subunit beta type-10Homo sapiens (human)IC50 (µMol)0.25900.00130.81515.0000AID277357
Proteasome subunit beta type-3Homo sapiens (human)IC50 (µMol)0.25900.00130.70995.0000AID277357
Proteasome subunit beta type-2Homo sapiens (human)IC50 (µMol)14.50300.00131.39067.9540AID1382146; AID1382149; AID277357
Proteasome subunit alpha type-6Homo sapiens (human)IC50 (µMol)0.25900.00130.70995.0000AID277357
Splicing factor 3B subunit 3Homo sapiens (human)IC50 (µMol)6.74050.01090.93893.4810AID506784; AID507021
Proteasome subunit alpha-type 8Homo sapiens (human)IC50 (µMol)0.25900.00130.70995.0000AID277357
Proteasome subunit beta type-7Homo sapiens (human)IC50 (µMol)0.25900.00130.68435.0000AID277357
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (33)

Processvia Protein(s)Taxonomy
proteolysisProteasome subunit beta type-11Homo sapiens (human)
T cell differentiation in thymusProteasome subunit beta type-11Homo sapiens (human)
CD8-positive, alpha-beta T cell differentiationProteasome subunit beta type-11Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-11Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit alpha type-7Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-1Homo sapiens (human)
proteolysis involved in protein catabolic processProteasome subunit beta type-1Homo sapiens (human)
immune system processProteasome subunit alpha type-1Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusProteasome subunit alpha type-1Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit alpha type-1Homo sapiens (human)
response to virusProteasome subunit alpha type-2Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit alpha type-2Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit alpha type-3Homo sapiens (human)
regulation of endopeptidase activityProteasome subunit alpha type-3Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit alpha type-4Homo sapiens (human)
antigen processing and presentationProteasome subunit beta type-8Homo sapiens (human)
fat cell differentiationProteasome subunit beta type-8Homo sapiens (human)
regulation of endopeptidase activityProteasome subunit beta type-8Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-8Homo sapiens (human)
immune system processProteasome subunit beta type-9Homo sapiens (human)
regulation of cysteine-type endopeptidase activityProteasome subunit beta type-9Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-9Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit alpha type-5Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusProteasome subunit beta type-4Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-4Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-6Homo sapiens (human)
proteolysisProteasome subunit beta type-5Homo sapiens (human)
response to oxidative stressProteasome subunit beta type-5Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-5Homo sapiens (human)
cell morphogenesisProteasome subunit beta type-10Homo sapiens (human)
humoral immune responseProteasome subunit beta type-10Homo sapiens (human)
T cell proliferationProteasome subunit beta type-10Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-10Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-3Homo sapiens (human)
response to organonitrogen compoundProteasome subunit beta type-2Homo sapiens (human)
response to organic cyclic compoundProteasome subunit beta type-2Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-2Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit alpha type-6Homo sapiens (human)
regulation of inflammatory responseProteasome subunit alpha type-6Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityProteasome subunit alpha type-6Homo sapiens (human)
proteolysis involved in protein catabolic processProteasome subunit alpha type-6Homo sapiens (human)
RNA splicing, via transesterification reactionsSplicing factor 3B subunit 3Homo sapiens (human)
mRNA splicing, via spliceosomeSplicing factor 3B subunit 3Homo sapiens (human)
regulation of DNA repairSplicing factor 3B subunit 3Homo sapiens (human)
RNA splicingSplicing factor 3B subunit 3Homo sapiens (human)
negative regulation of protein catabolic processSplicing factor 3B subunit 3Homo sapiens (human)
regulation of RNA splicingSplicing factor 3B subunit 3Homo sapiens (human)
positive regulation of DNA-templated transcriptionSplicing factor 3B subunit 3Homo sapiens (human)
U2-type prespliceosome assemblySplicing factor 3B subunit 3Homo sapiens (human)
spermatogenesisProteasome subunit alpha-type 8Homo sapiens (human)
proteasomal protein catabolic processProteasome subunit alpha-type 8Homo sapiens (human)
cell differentiationProteasome subunit alpha-type 8Homo sapiens (human)
meiotic cell cycleProteasome subunit alpha-type 8Homo sapiens (human)
regulation of meiosis IProteasome subunit alpha-type 8Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit alpha-type 8Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (13)

Processvia Protein(s)Taxonomy
threonine-type endopeptidase activityProteasome subunit beta type-11Homo sapiens (human)
protein bindingProteasome subunit beta type-11Homo sapiens (human)
peptidase activityProteasome subunit beta type-11Homo sapiens (human)
endopeptidase activityProteasome subunit beta type-11Homo sapiens (human)
protein bindingProteasome subunit alpha type-7Homo sapiens (human)
identical protein bindingProteasome subunit alpha type-7Homo sapiens (human)
protein bindingProteasome subunit beta type-1Homo sapiens (human)
lipopolysaccharide bindingProteasome subunit alpha type-1Homo sapiens (human)
protein bindingProteasome subunit alpha type-1Homo sapiens (human)
protein bindingProteasome subunit alpha type-2Homo sapiens (human)
protein bindingProteasome subunit alpha type-3Homo sapiens (human)
ubiquitin protein ligase bindingProteasome subunit alpha type-3Homo sapiens (human)
protein bindingProteasome subunit alpha type-4Homo sapiens (human)
threonine-type endopeptidase activityProteasome subunit beta type-8Homo sapiens (human)
protein bindingProteasome subunit beta type-8Homo sapiens (human)
endopeptidase activityProteasome subunit beta type-8Homo sapiens (human)
threonine-type endopeptidase activityProteasome subunit beta type-9Homo sapiens (human)
protein bindingProteasome subunit beta type-9Homo sapiens (human)
endopeptidase activityProteasome subunit beta type-9Homo sapiens (human)
protein bindingProteasome subunit alpha type-5Homo sapiens (human)
lipopolysaccharide bindingProteasome subunit beta type-4Homo sapiens (human)
protein bindingProteasome subunit beta type-4Homo sapiens (human)
endopeptidase activityProteasome subunit beta type-6Homo sapiens (human)
threonine-type endopeptidase activityProteasome subunit beta type-6Homo sapiens (human)
protein bindingProteasome subunit beta type-6Homo sapiens (human)
cadherin bindingProteasome subunit beta type-6Homo sapiens (human)
threonine-type endopeptidase activityProteasome subunit beta type-5Homo sapiens (human)
protein bindingProteasome subunit beta type-5Homo sapiens (human)
peptidase activityProteasome subunit beta type-5Homo sapiens (human)
endopeptidase activityProteasome subunit beta type-5Homo sapiens (human)
threonine-type endopeptidase activityProteasome subunit beta type-10Homo sapiens (human)
protein bindingProteasome subunit beta type-10Homo sapiens (human)
endopeptidase activityProteasome subunit beta type-10Homo sapiens (human)
protein bindingProteasome subunit beta type-3Homo sapiens (human)
protein bindingProteasome subunit beta type-2Homo sapiens (human)
RNA bindingProteasome subunit alpha type-6Homo sapiens (human)
endopeptidase activityProteasome subunit alpha type-6Homo sapiens (human)
protein bindingProteasome subunit alpha type-6Homo sapiens (human)
purine ribonucleoside triphosphate bindingProteasome subunit alpha type-6Homo sapiens (human)
NF-kappaB bindingProteasome subunit alpha type-6Homo sapiens (human)
protein bindingSplicing factor 3B subunit 3Homo sapiens (human)
protein-containing complex bindingSplicing factor 3B subunit 3Homo sapiens (human)
U2 snRNA bindingSplicing factor 3B subunit 3Homo sapiens (human)
threonine-type endopeptidase activityProteasome subunit beta type-7Homo sapiens (human)
protein bindingProteasome subunit beta type-7Homo sapiens (human)
endopeptidase activityProteasome subunit beta type-7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (34)

Processvia Protein(s)Taxonomy
cytosolProteasome subunit beta type-11Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-11Homo sapiens (human)
nucleusProteasome subunit beta type-11Homo sapiens (human)
cytosolProteasome subunit beta type-11Homo sapiens (human)
nucleusProteasome subunit alpha type-7Homo sapiens (human)
cytoplasmProteasome subunit alpha type-7Homo sapiens (human)
proteasome complexProteasome subunit alpha type-7Homo sapiens (human)
nucleusProteasome subunit alpha type-7Homo sapiens (human)
nucleoplasmProteasome subunit alpha type-7Homo sapiens (human)
cytosolProteasome subunit alpha type-7Homo sapiens (human)
extracellular exosomeProteasome subunit alpha type-7Homo sapiens (human)
postsynapseProteasome subunit alpha type-7Homo sapiens (human)
proteasome core complexProteasome subunit alpha type-7Homo sapiens (human)
proteasome core complex, alpha-subunit complexProteasome subunit alpha type-7Homo sapiens (human)
nucleusProteasome subunit beta type-1Homo sapiens (human)
cytoplasmProteasome subunit beta type-1Homo sapiens (human)
proteasome complexProteasome subunit beta type-1Homo sapiens (human)
extracellular regionProteasome subunit beta type-1Homo sapiens (human)
nucleusProteasome subunit beta type-1Homo sapiens (human)
nucleoplasmProteasome subunit beta type-1Homo sapiens (human)
cytosolProteasome subunit beta type-1Homo sapiens (human)
secretory granule lumenProteasome subunit beta type-1Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-1Homo sapiens (human)
ficolin-1-rich granule lumenProteasome subunit beta type-1Homo sapiens (human)
proteasome core complexProteasome subunit beta type-1Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-1Homo sapiens (human)
nucleusProteasome subunit alpha type-1Homo sapiens (human)
cytoplasmProteasome subunit alpha type-1Homo sapiens (human)
proteasome complexProteasome subunit alpha type-1Homo sapiens (human)
nucleusProteasome subunit alpha type-1Homo sapiens (human)
nucleoplasmProteasome subunit alpha type-1Homo sapiens (human)
centrosomeProteasome subunit alpha type-1Homo sapiens (human)
cytosolProteasome subunit alpha type-1Homo sapiens (human)
extracellular exosomeProteasome subunit alpha type-1Homo sapiens (human)
proteasome core complexProteasome subunit alpha type-1Homo sapiens (human)
proteasome core complex, alpha-subunit complexProteasome subunit alpha type-1Homo sapiens (human)
nucleusProteasome subunit alpha type-2Homo sapiens (human)
cytoplasmProteasome subunit alpha type-2Homo sapiens (human)
proteasome complexProteasome subunit alpha type-2Homo sapiens (human)
P-bodyProteasome subunit alpha type-2Homo sapiens (human)
extracellular regionProteasome subunit alpha type-2Homo sapiens (human)
nucleusProteasome subunit alpha type-2Homo sapiens (human)
nucleoplasmProteasome subunit alpha type-2Homo sapiens (human)
cytosolProteasome subunit alpha type-2Homo sapiens (human)
secretory granule lumenProteasome subunit alpha type-2Homo sapiens (human)
extracellular exosomeProteasome subunit alpha type-2Homo sapiens (human)
ficolin-1-rich granule lumenProteasome subunit alpha type-2Homo sapiens (human)
proteasome core complexProteasome subunit alpha type-2Homo sapiens (human)
proteasome core complex, alpha-subunit complexProteasome subunit alpha type-2Homo sapiens (human)
nucleusProteasome subunit alpha type-3Homo sapiens (human)
cytoplasmProteasome subunit alpha type-3Homo sapiens (human)
proteasome complexProteasome subunit alpha type-3Homo sapiens (human)
nucleusProteasome subunit alpha type-3Homo sapiens (human)
nucleoplasmProteasome subunit alpha type-3Homo sapiens (human)
cytoplasmProteasome subunit alpha type-3Homo sapiens (human)
cytosolProteasome subunit alpha type-3Homo sapiens (human)
extracellular exosomeProteasome subunit alpha type-3Homo sapiens (human)
proteasome core complexProteasome subunit alpha type-3Homo sapiens (human)
proteasome core complex, alpha-subunit complexProteasome subunit alpha type-3Homo sapiens (human)
synapseProteasome subunit alpha type-3Homo sapiens (human)
nucleusProteasome subunit alpha type-4Homo sapiens (human)
cytoplasmProteasome subunit alpha type-4Homo sapiens (human)
proteasome complexProteasome subunit alpha type-4Homo sapiens (human)
P-bodyProteasome subunit alpha type-4Homo sapiens (human)
nucleusProteasome subunit alpha type-4Homo sapiens (human)
nucleoplasmProteasome subunit alpha type-4Homo sapiens (human)
cytosolProteasome subunit alpha type-4Homo sapiens (human)
intracellular membrane-bounded organelleProteasome subunit alpha type-4Homo sapiens (human)
extracellular exosomeProteasome subunit alpha type-4Homo sapiens (human)
proteasome core complexProteasome subunit alpha type-4Homo sapiens (human)
proteasome core complex, alpha-subunit complexProteasome subunit alpha type-4Homo sapiens (human)
cytosolProteasome subunit alpha type-4Homo sapiens (human)
nucleoplasmProteasome subunit beta type-8Homo sapiens (human)
cytosolProteasome subunit beta type-8Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-8Homo sapiens (human)
proteasome complexProteasome subunit beta type-8Homo sapiens (human)
proteasome core complexProteasome subunit beta type-8Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-8Homo sapiens (human)
spermatoproteasome complexProteasome subunit beta type-8Homo sapiens (human)
nucleusProteasome subunit beta type-8Homo sapiens (human)
cytosolProteasome subunit beta type-8Homo sapiens (human)
nucleoplasmProteasome subunit beta type-9Homo sapiens (human)
cytosolProteasome subunit beta type-9Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-9Homo sapiens (human)
proteasome complexProteasome subunit beta type-9Homo sapiens (human)
proteasome core complexProteasome subunit beta type-9Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-9Homo sapiens (human)
spermatoproteasome complexProteasome subunit beta type-9Homo sapiens (human)
cytosolProteasome subunit beta type-9Homo sapiens (human)
nucleusProteasome subunit beta type-9Homo sapiens (human)
nucleusProteasome subunit alpha type-5Homo sapiens (human)
cytoplasmProteasome subunit alpha type-5Homo sapiens (human)
proteasome complexProteasome subunit alpha type-5Homo sapiens (human)
extracellular regionProteasome subunit alpha type-5Homo sapiens (human)
nucleusProteasome subunit alpha type-5Homo sapiens (human)
nucleoplasmProteasome subunit alpha type-5Homo sapiens (human)
cytosolProteasome subunit alpha type-5Homo sapiens (human)
secretory granule lumenProteasome subunit alpha type-5Homo sapiens (human)
extracellular exosomeProteasome subunit alpha type-5Homo sapiens (human)
ficolin-1-rich granule lumenProteasome subunit alpha type-5Homo sapiens (human)
proteasome core complexProteasome subunit alpha type-5Homo sapiens (human)
proteasome core complex, alpha-subunit complexProteasome subunit alpha type-5Homo sapiens (human)
nucleusProteasome subunit beta type-4Homo sapiens (human)
cytoplasmProteasome subunit beta type-4Homo sapiens (human)
proteasome complexProteasome subunit beta type-4Homo sapiens (human)
nucleusProteasome subunit beta type-4Homo sapiens (human)
nucleoplasmProteasome subunit beta type-4Homo sapiens (human)
mitochondrionProteasome subunit beta type-4Homo sapiens (human)
cytosolProteasome subunit beta type-4Homo sapiens (human)
ciliary basal bodyProteasome subunit beta type-4Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-4Homo sapiens (human)
proteasome core complexProteasome subunit beta type-4Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-4Homo sapiens (human)
cytosolProteasome subunit beta type-4Homo sapiens (human)
nucleusProteasome subunit beta type-6Homo sapiens (human)
cytoplasmProteasome subunit beta type-6Homo sapiens (human)
proteasome complexProteasome subunit beta type-6Homo sapiens (human)
nucleusProteasome subunit beta type-6Homo sapiens (human)
nucleoplasmProteasome subunit beta type-6Homo sapiens (human)
mitochondrionProteasome subunit beta type-6Homo sapiens (human)
cytosolProteasome subunit beta type-6Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-6Homo sapiens (human)
proteasome core complexProteasome subunit beta type-6Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-6Homo sapiens (human)
cytosolProteasome subunit beta type-6Homo sapiens (human)
nucleusProteasome subunit beta type-5Homo sapiens (human)
cytoplasmProteasome subunit beta type-5Homo sapiens (human)
proteasome complexProteasome subunit beta type-5Homo sapiens (human)
nucleusProteasome subunit beta type-5Homo sapiens (human)
nucleoplasmProteasome subunit beta type-5Homo sapiens (human)
centrosomeProteasome subunit beta type-5Homo sapiens (human)
cytosolProteasome subunit beta type-5Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-5Homo sapiens (human)
proteasome core complexProteasome subunit beta type-5Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-5Homo sapiens (human)
cytosolProteasome subunit beta type-5Homo sapiens (human)
nucleoplasmProteasome subunit beta type-10Homo sapiens (human)
cytosolProteasome subunit beta type-10Homo sapiens (human)
proteasome complexProteasome subunit beta type-10Homo sapiens (human)
proteasome core complexProteasome subunit beta type-10Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-10Homo sapiens (human)
spermatoproteasome complexProteasome subunit beta type-10Homo sapiens (human)
cytosolProteasome subunit beta type-10Homo sapiens (human)
nucleusProteasome subunit beta type-10Homo sapiens (human)
nucleusProteasome subunit beta type-3Homo sapiens (human)
cytoplasmProteasome subunit beta type-3Homo sapiens (human)
proteasome complexProteasome subunit beta type-3Homo sapiens (human)
nucleusProteasome subunit beta type-3Homo sapiens (human)
nucleoplasmProteasome subunit beta type-3Homo sapiens (human)
cytosolProteasome subunit beta type-3Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-3Homo sapiens (human)
proteasome core complexProteasome subunit beta type-3Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-3Homo sapiens (human)
cytosolProteasome subunit beta type-3Homo sapiens (human)
nucleusProteasome subunit beta type-2Homo sapiens (human)
cytoplasmProteasome subunit beta type-2Homo sapiens (human)
proteasome complexProteasome subunit beta type-2Homo sapiens (human)
nucleusProteasome subunit beta type-2Homo sapiens (human)
nucleoplasmProteasome subunit beta type-2Homo sapiens (human)
cytosolProteasome subunit beta type-2Homo sapiens (human)
membraneProteasome subunit beta type-2Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-2Homo sapiens (human)
proteasome core complexProteasome subunit beta type-2Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-2Homo sapiens (human)
cytosolProteasome subunit beta type-2Homo sapiens (human)
nucleusProteasome subunit alpha type-6Homo sapiens (human)
cytoplasmProteasome subunit alpha type-6Homo sapiens (human)
proteasome complexProteasome subunit alpha type-6Homo sapiens (human)
P-bodyProteasome subunit alpha type-6Homo sapiens (human)
nucleusProteasome subunit alpha type-6Homo sapiens (human)
nucleoplasmProteasome subunit alpha type-6Homo sapiens (human)
cytosolProteasome subunit alpha type-6Homo sapiens (human)
ribosomeProteasome subunit alpha type-6Homo sapiens (human)
nuclear matrixProteasome subunit alpha type-6Homo sapiens (human)
myofibrilProteasome subunit alpha type-6Homo sapiens (human)
sarcomereProteasome subunit alpha type-6Homo sapiens (human)
extracellular exosomeProteasome subunit alpha type-6Homo sapiens (human)
proteasome core complexProteasome subunit alpha type-6Homo sapiens (human)
proteasome core complex, alpha-subunit complexProteasome subunit alpha type-6Homo sapiens (human)
SAGA complexSplicing factor 3B subunit 3Homo sapiens (human)
nucleusSplicing factor 3B subunit 3Homo sapiens (human)
nucleoplasmSplicing factor 3B subunit 3Homo sapiens (human)
spliceosomal complexSplicing factor 3B subunit 3Homo sapiens (human)
U2-type spliceosomal complexSplicing factor 3B subunit 3Homo sapiens (human)
U2 snRNPSplicing factor 3B subunit 3Homo sapiens (human)
nucleolusSplicing factor 3B subunit 3Homo sapiens (human)
U12-type spliceosomal complexSplicing factor 3B subunit 3Homo sapiens (human)
U2-type precatalytic spliceosomeSplicing factor 3B subunit 3Homo sapiens (human)
catalytic step 2 spliceosomeSplicing factor 3B subunit 3Homo sapiens (human)
nucleusSplicing factor 3B subunit 3Homo sapiens (human)
nucleusProteasome subunit alpha-type 8Homo sapiens (human)
cytosolProteasome subunit alpha-type 8Homo sapiens (human)
extracellular exosomeProteasome subunit alpha-type 8Homo sapiens (human)
proteasome core complex, alpha-subunit complexProteasome subunit alpha-type 8Homo sapiens (human)
spermatoproteasome complexProteasome subunit alpha-type 8Homo sapiens (human)
nucleusProteasome subunit alpha-type 8Homo sapiens (human)
nucleusProteasome subunit beta type-7Homo sapiens (human)
cytoplasmProteasome subunit beta type-7Homo sapiens (human)
proteasome complexProteasome subunit beta type-7Homo sapiens (human)
extracellular regionProteasome subunit beta type-7Homo sapiens (human)
nucleusProteasome subunit beta type-7Homo sapiens (human)
nucleoplasmProteasome subunit beta type-7Homo sapiens (human)
cytosolProteasome subunit beta type-7Homo sapiens (human)
nuclear bodyProteasome subunit beta type-7Homo sapiens (human)
secretory granule lumenProteasome subunit beta type-7Homo sapiens (human)
ficolin-1-rich granule lumenProteasome subunit beta type-7Homo sapiens (human)
proteasome core complexProteasome subunit beta type-7Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-7Homo sapiens (human)
cytosolProteasome subunit beta type-7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (75)

Assay IDTitleYearJournalArticle
AID1128235Inhibition of beta5i subunit of immunoproteasome (unknown origin) by active-site ELISA2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Structurally novel highly potent proteasome inhibitors created by the structure-based hybridization of nonpeptidic belactosin derivatives and peptide boronates.
AID360422Inhibition of proteosome activity in rat PC12 cells at 0.3 uM after 24 hrs relative to control2007The Journal of biological chemistry, Feb-16, Volume: 282, Issue:7
Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease.
AID360682Reversal of increase in glutathione level in rat PC12 cells at 1 uM in presence of 10 uM wortmannin after 24 hrs relative to control2007The Journal of biological chemistry, Feb-16, Volume: 282, Issue:7
Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease.
AID1204607Inhibition of chymotrypsin-like activity of human beta-5 subunit of 20S proteasome using Suc-LLVY-AMC as substrate by fluorometer analysis2015European journal of medicinal chemistry, Jun-15, Volume: 98Discovery of novel non-covalent inhibitors selective to the β5-subunit of the human 20S proteasome.
AID1595605Cytotoxicity against human NCI-H727 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib.
AID1382149Inhibition of trypsin-like activity of human 26S proteasome using Boc-LRR-MCA as substrate measured for 1 hr by fluorescence assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Ridaifen-F conjugated with cell-penetrating peptides inhibits intracellular proteasome activities and induces drug-resistant cell death.
AID734748Inhibition of chymotrypsin-like activity of human 20S immunoproteasome beta 5 subunit using biotin-(CH2)4-Leu-Leu-Leu-epoxyketone as substrate at 2.5 uM incubated for 5 mins prior to substrate addition measured after 1 hr by ELISA2013Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
Potent proteasome inhibitors derived from the unnatural cis-cyclopropane isomer of Belactosin A: synthesis, biological activity, and mode of action.
AID1382145Inhibition of PGPH activity of human 20S proteasome using Z-LLE-MCA as substrate measured for 1 hr by fluorescence assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Ridaifen-F conjugated with cell-penetrating peptides inhibits intracellular proteasome activities and induces drug-resistant cell death.
AID1382147Inhibition of chymotrypsin-like activity of human 20S proteasome using Suc-LLVY-MCA as substrate measured for 1 hr by fluorescence assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Ridaifen-F conjugated with cell-penetrating peptides inhibits intracellular proteasome activities and induces drug-resistant cell death.
AID737372Inhibition of chymotrypsin-like activity of proteasome beta5 subunit in human MDA-MB-468 cells using Suc-Leu-Leu-Val-Tyr-AMC as substrate after 2 hrs by fluorescence assay2013Journal of medicinal chemistry, May-23, Volume: 56, Issue:10
Oxadiazole-isopropylamides as potent and noncovalent proteasome inhibitors.
AID627858Antifungal activity against Candida albicans at 200 ug/ml after 24 hrs by NCCLS M27-P broth macrodilution method2011Journal of natural products, Aug-26, Volume: 74, Issue:8
Isolation, structure, and biological activities of Fellutamides C and D from an undescribed Metulocladosporiella (Chaetothyriales) using the genome-wide Candida albicans fitness test.
AID360688Translocation of Nrf2 protein to nucleus in rat PC12 cells at 1 uM around 6 or 9 hrs2007The Journal of biological chemistry, Feb-16, Volume: 282, Issue:7
Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease.
AID360683Reversal of increase in glutathione level in rat PC12 cells at 1 uM in presence of 30 uM PD-98059 after 24 hrs relative to control2007The Journal of biological chemistry, Feb-16, Volume: 282, Issue:7
Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease.
AID621520Inhibition of human 20S proteasome chymotrypsin-like activity using Suc-Leu-Leu-Val-Tyr-AMC fluorogenic substrate by fluorimetry2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
New betulinic acid derivatives as potent proteasome inhibitors.
AID360423Inhibition of proteosome activity in rat PC12 cells at 1 uM after 6 hrs relative to control2007The Journal of biological chemistry, Feb-16, Volume: 282, Issue:7
Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease.
AID640445Inhibition of 20S proteasome in human DLD1 cells transfected with 4Ub-Luc gene assessed as bioluminescence induction factor at 5 uM after 8 hrs by luciferase reporter gene assay relative to epoxomicin2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Semisynthetic neoboutomellerone derivatives as ubiquitin-proteasome pathway inhibitors.
AID360676Reversal of increase in glutathione level in rat PC12 cells at 1 uM in presence of 30 nM cycloheximide after 24 hrs relative to control2007The Journal of biological chemistry, Feb-16, Volume: 282, Issue:7
Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease.
AID360416Inhibition of 6-hydroxydopamine induced cytotoxicity in differentiated rat PC12 cells pretreated for 24 hrs by lactate dehydrogenase release assay2007The Journal of biological chemistry, Feb-16, Volume: 282, Issue:7
Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease.
AID360413Increase in glutathione level in differentiated rat PC12 cells after 24 hrs2007The Journal of biological chemistry, Feb-16, Volume: 282, Issue:7
Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease.
AID640444Inhibition of 20S proteasome activity in human DLD1 cells transfected with 4Ub-Luc gene assessed as bioluminescence induction factor at 10 uM after 8 hrs by luciferase reporter gene assay relative to epoxomicin2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Semisynthetic neoboutomellerone derivatives as ubiquitin-proteasome pathway inhibitors.
AID358765Prevention of proteasome mediated degradation of FKBP12-YFP fusion protein expressed in mouse NIH3T3 cells at 10 uM2007The Journal of biological chemistry, Aug-24, Volume: 282, Issue:34
A directed approach for engineering conditional protein stability using biologically silent small molecules.
AID360425Inhibition of hydrogen peroxide induced cytotoxicity in rat PC12 cells pretreated for 24 hrs by MTT assay2007The Journal of biological chemistry, Feb-16, Volume: 282, Issue:7
Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease.
AID360668Inhibition of 150 uM 6-hydroxydopamine induced ROS production in rat PC12 cells pretreated for 24 hrs by MTT assay2007The Journal of biological chemistry, Feb-16, Volume: 282, Issue:7
Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease.
AID360675Reversal of increase in glutathione level in rat PC12 cells at 1 uM in presence of 10 nM cycloheximide after 24 hrs relative to control2007The Journal of biological chemistry, Feb-16, Volume: 282, Issue:7
Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease.
AID506769Displacement of [3H]probe from SAP130 in human WiDr cells assessed as radioactive intensity at 500 nM after 1 hr by scintillation counting relative to control2007Nature chemical biology, Sep, Volume: 3, Issue:9
Splicing factor SF3b as a target of the antitumor natural product pladienolide.
AID640520Inhibition of peptide-glutamyl-peptide-hydrolyzing activity of 20S proteasome in human DLD1 cells transfected with 4Ub-Luc gene using Z-Leu-Leu-Glu-AMC as substrate after 6 hrs by spectrofluorometric analysis2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Semisynthetic neoboutomellerone derivatives as ubiquitin-proteasome pathway inhibitors.
AID717312Inhibition of proteasome activity in human HeLa cells transfected with UbG76V-GFP assessed as accumulation of UbG76V-GFP at 4 ug/mL after 24 hrs by fluorescence microscopy2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Synthesis and biological evaluation of novel spin labeled 18β-glycyrrhetinic acid derivatives.
AID360681Reversal of increase in glutathione level in rat PC12 cells at 1 uM in presence of 3 uM BIM after 24 hrs relative to control2007The Journal of biological chemistry, Feb-16, Volume: 282, Issue:7
Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease.
AID640446Inhibition of 20S proteasome in human DLD1 cells transfected with 4Ub-Luc gene assessed as bioluminescence induction factor at 1 uM after 8 hrs by luciferase reporter gene assay relative to epoxomicin2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Semisynthetic neoboutomellerone derivatives as ubiquitin-proteasome pathway inhibitors.
AID343738Inhibition of trypsin-like activity of human 20S proteasome2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Synthesis and proteasome inhibition of glycyrrhetinic acid derivatives.
AID1128234Inhibition of beta5 subunit of immunoproteasome (unknown origin) by active-site ELISA2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
Structurally novel highly potent proteasome inhibitors created by the structure-based hybridization of nonpeptidic belactosin derivatives and peptide boronates.
AID1382150Inhibition of chymotrypsin-like activity of human 26S proteasome using Suc-LLVY-MCA as substrate measured for 1 hr by fluorescence assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Ridaifen-F conjugated with cell-penetrating peptides inhibits intracellular proteasome activities and induces drug-resistant cell death.
AID506784Inhibition of SAP130 mediated cell growth in human WiDr cells2007Nature chemical biology, Sep, Volume: 3, Issue:9
Splicing factor SF3b as a target of the antitumor natural product pladienolide.
AID507021Inhibition of SAP130 in VEGF-stimulated human U251 cells by PLAP reporter gene assay2007Nature chemical biology, Sep, Volume: 3, Issue:9
Splicing factor SF3b as a target of the antitumor natural product pladienolide.
AID360680Reversal of increase in glutathione level in rat PC12 cells at 1 uM in presence of 30 uM SB-203580 after 24 hrs relative to control2007The Journal of biological chemistry, Feb-16, Volume: 282, Issue:7
Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease.
AID343739Inhibition of caspase-like activity of human 20S proteasome2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Synthesis and proteasome inhibition of glycyrrhetinic acid derivatives.
AID360420Inhibition of proteosome activity in rat PC12 cells at 0.1 uM after 24 hrs relative to control2007The Journal of biological chemistry, Feb-16, Volume: 282, Issue:7
Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease.
AID360687Inhibition of 6-hydroxydopamine-induced cytotoxicity in rat PC12 cells pretreated for 24 hrs by MTT assay2007The Journal of biological chemistry, Feb-16, Volume: 282, Issue:7
Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease.
AID640519Inhibition of 20S proteasome in human DLD1 cells transfected with 4Ub-Luc gene assessed as bioluminescence induction factor at 0.1 uM after 8 hrs by luciferase reporter gene assay relative to epoxomicin2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Semisynthetic neoboutomellerone derivatives as ubiquitin-proteasome pathway inhibitors.
AID360667Inhibition of 300 uM hydrogen peroxide induced ROS production in rat PC12 cells pretreated at 1 uM for 24 hrs by MTT assay2007The Journal of biological chemistry, Feb-16, Volume: 282, Issue:7
Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease.
AID506773Displacement of [3H]probe from SAP130 in human WiDr cell immunoprecipitate sample assessed as radioactive intensity at 10 uM after 1 hr by scintillation counting2007Nature chemical biology, Sep, Volume: 3, Issue:9
Splicing factor SF3b as a target of the antitumor natural product pladienolide.
AID277357Inhibition of human 20S proteasome2007Journal of natural products, Feb, Volume: 70, Issue:2
Cinnabaramides A-G: analogues of lactacystin and salinosporamide from a terrestrial streptomycete.
AID360686Reversal of increase in GLCLC subunit mRNA expression in rat PC12 cells at 1 uM after 12 hrs in presence of p38 MAPK inhibitor SB-2035802007The Journal of biological chemistry, Feb-16, Volume: 282, Issue:7
Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease.
AID360414Reversal of cytoprotection activity in rat PC12 cells pretreated at 1 uM for 24 hrs in presence of p38 MAPK inhibitor SB-2035802007The Journal of biological chemistry, Feb-16, Volume: 282, Issue:7
Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease.
AID360669Inhibition of 200 uM hydrogen peroxide induced ROS production in rat PC12 cells pretreated for 24 hrs by MTT assay2007The Journal of biological chemistry, Feb-16, Volume: 282, Issue:7
Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease.
AID360417Increase in reduced glutathione level in rat PC12 cells after 24 hrs2007The Journal of biological chemistry, Feb-16, Volume: 282, Issue:7
Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease.
AID360419Inhibition of proteosome activity in rat PC12 cells at 0.1 uM after 6 hrs relative to control2007The Journal of biological chemistry, Feb-16, Volume: 282, Issue:7
Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease.
AID640521Inhibition of chymotrypsin-like activity of 20S proteasome in human DLD1 cells transfected with 4Ub-Luc gene using Succinyl-Leu-Leu-Val-Tyr-AMC as substrate after 6 hrs by spectrofluorometric analysis2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Semisynthetic neoboutomellerone derivatives as ubiquitin-proteasome pathway inhibitors.
AID737375Reversible inhibition of chymotrypsin-like activity of rabbit 20s proteasome beta5 subunit at 2.5 uM after 18 hrs by dialysis method2013Journal of medicinal chemistry, May-23, Volume: 56, Issue:10
Oxadiazole-isopropylamides as potent and noncovalent proteasome inhibitors.
AID360421Inhibition of proteosome activity in rat PC12 cells at 0.3 uM after 6 hrs relative to control2007The Journal of biological chemistry, Feb-16, Volume: 282, Issue:7
Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease.
AID506770Displacement of [3H]probe from SAP130 in human WiDr cell immunoprecipitate sample assessed as radioactive intensity at 500 nM after 1 hr by scintillation counting relative to control2007Nature chemical biology, Sep, Volume: 3, Issue:9
Splicing factor SF3b as a target of the antitumor natural product pladienolide.
AID1382148Inhibition of PGPH activity of human 26S proteasome using Z-LLE-MCA as substrate measured for 1 hr by fluorescence assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Ridaifen-F conjugated with cell-penetrating peptides inhibits intracellular proteasome activities and induces drug-resistant cell death.
AID1595606Selectivity ratio of IC50 for human NCI-H727 cells to IC50 for human NCI-H23 cells2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib.
AID1382146Inhibition of trypsin-like activity of human 20S proteasome using Boc-LRR-MCA as substrate measured for 1 hr by fluorescence assay2018European journal of medicinal chemistry, Feb-25, Volume: 146Ridaifen-F conjugated with cell-penetrating peptides inhibits intracellular proteasome activities and induces drug-resistant cell death.
AID360415Inhibition of 6-hydroxydopamine induced cytotoxicity in differentiated rat PC12 cells pretreated for 24 hrs by MTT assay2007The Journal of biological chemistry, Feb-16, Volume: 282, Issue:7
Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease.
AID360674Increase in oxidized glutathione level in rat PC12 cells at 1 uM after 12 hrs2007The Journal of biological chemistry, Feb-16, Volume: 282, Issue:7
Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease.
AID360685Increase in GLCLC subunit mRNA expression in rat PC12 cells at 1 uM after 12 hrs2007The Journal of biological chemistry, Feb-16, Volume: 282, Issue:7
Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease.
AID717314Inhibition of chymotrypsin-like activity of human 20S proteasome using Suc-Leu-Leu-Val-Tyr-AMC as substrate by fluorometric assay2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Synthesis and biological evaluation of novel spin labeled 18β-glycyrrhetinic acid derivatives.
AID360677Reversal of increase in glutathione level in rat PC12 cells at 1 uM in presence of 100 nM cycloheximide after 24 hrs relative to control2007The Journal of biological chemistry, Feb-16, Volume: 282, Issue:7
Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease.
AID360678Reversal of increase in glutathione level in rat PC12 cells at 1 uM in presence of 3 uM SB-203580 after 24 hrs relative to control2007The Journal of biological chemistry, Feb-16, Volume: 282, Issue:7
Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease.
AID360672Increase in reduced glutathione level in rat PC12 cells at 1 uM after 24 hrs2007The Journal of biological chemistry, Feb-16, Volume: 282, Issue:7
Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease.
AID360666Inhibition of 300 uM 6-hydroxydopamine induced ROS production in rat PC12 cells pretreated at 1 uM for 24 hrs by MTT assay2007The Journal of biological chemistry, Feb-16, Volume: 282, Issue:7
Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease.
AID360684Reversal of increase in glutathione level in rat PC12 cells at 1 uM in presence of 10 uM SP600125 after 24 hrs relative to control2007The Journal of biological chemistry, Feb-16, Volume: 282, Issue:7
Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease.
AID590339Inhibition of chymotrypsin-like activity of 20S proteasome2011Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
Synthesis and proteasome inhibition of lithocholic acid derivatives.
AID737378Covalent binding affinity to rabbit 20s proteasome beta5 subunit assessed as modification of TTTLAFK peptide after 30 mins by LC-MS/MS analysis2013Journal of medicinal chemistry, May-23, Volume: 56, Issue:10
Oxadiazole-isopropylamides as potent and noncovalent proteasome inhibitors.
AID360679Reversal of increase in glutathione level in rat PC12 cells at 1 uM in presence of 10 uM SB-203580 after 24 hrs relative to control2007The Journal of biological chemistry, Feb-16, Volume: 282, Issue:7
Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease.
AID734750Inhibition of chymotrypsin-like activity of human constitutive 20S proteasome beta 5 subunit using biotin-(CH2)4-Leu-Leu-Leu-epoxyketone as substrate at 2.5 uM incubated for 5 mins prior to substrate addition measured after 1 hr by ELISA2013Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
Potent proteasome inhibitors derived from the unnatural cis-cyclopropane isomer of Belactosin A: synthesis, biological activity, and mode of action.
AID343737Inhibition of chymotrypsin-like activity of human 20S proteasome2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
Synthesis and proteasome inhibition of glycyrrhetinic acid derivatives.
AID655579Inhibition of chymotrypsin-like activity of human 20s proteasome2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Design and synthesis of naphthoquinone derivatives as antiproliferative agents and 20S proteasome inhibitors.
AID1595604Cytotoxicity against human NCI-H23 cells after 72 hrs by CellTiter 96 AQueous one solution cell proliferation assay2019Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
Development of Novel Epoxyketone-Based Proteasome Inhibitors as a Strategy To Overcome Cancer Resistance to Carfilzomib and Bortezomib.
AID360424Inhibition of proteosome activity in rat PC12 cells at 1 uM after 24 hrs relative to control2007The Journal of biological chemistry, Feb-16, Volume: 282, Issue:7
Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease.
AID360673Increase in oxidized glutathione level in rat PC12 cells at 1 uM after 24 hrs2007The Journal of biological chemistry, Feb-16, Volume: 282, Issue:7
Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (903)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's178 (19.71)18.2507
2000's539 (59.69)29.6817
2010's179 (19.82)24.3611
2020's7 (0.78)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.03

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.03 (24.57)
Research Supply Index6.83 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index48.73 (26.88)
Search Engine Supply Index2.02 (0.95)

This Compound (33.03)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.11%)5.53%
Reviews22 (2.39%)6.00%
Case Studies2 (0.22%)4.05%
Observational0 (0.00%)0.25%
Other895 (97.28%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]